{
    "clinical_study": {
        "@rank": "87468", 
        "acronym": "DEXCAR-0212", 
        "arm_group": [
            {
                "arm_group_label": "Dexamethasone", 
                "description": "Intervention group"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Placebo group (physiological saline)"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothesis: Administration of corticoids (dexamethasone) together with the conventional\n      antibiotherapy in the acute phase of a febrile urinary tract infection could reduce the risk\n      of renal scarring after 6 months of the primo-infection.\n\n      Primary objectives:To evaluate the reduction in incidence of renal scarring after 6 months\n      of a acute pyelonephritis between the control group (conventional therapy plus placebo) and\n      intervention group (conventional therapy plus dexamethasone.\n\n      Design: Multicentre randomized clinical trial,placebo controled, including children between\n      2 months and 14 years with a acute pyelonephritis proven by a acute phase DMSA\n      (dimethylsuccinic acid ). A total of 180 children in to parallel groups (intervention and\n      placebo) will be included."
        }, 
        "brief_title": "Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Pyelonephritis", 
        "condition_browse": {
            "mesh_term": [
                "Pyelonephritis", 
                "Urinary Tract Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "The urinary tract infection (UTI) is one of the most common bacterial infections in\n      children. These infections can be grouped clinically as asymptomatic bacteriuria , cystitis\n      (lower urinary tract infection ) and acute pyelonephritis (APN ) when the infection reaches\n      the upper urinary tract. This classification is of great clinical relevance because while\n      cystitis is usually a benign condition without further complications , the APN is associated\n      with an increased risk of kidney damage, acquired through renal scarring . Renal scarring is\n      a consequence of the inflammatory and immune response that is triggered to eradicate the\n      bacteria involved in the UTI. Parenchymal infection can be solved , but there are a number\n      of poorly understood factors that may perpetuate inflammation and this would promote the\n      formation of scar nephritis. One of the most relevant factors involved in the renal scarring\n      development are the production of inflammatory mediators (complement proteins, bactericidal\n      peptides, cytokines such as IL6 and IL8, chemokines, and adhesion molecules defensins).\n      Thus, it is obvious to think that the use of anti-inflammatory drugs may prevent the release\n      of these mediators and the development of permanent kidney damage.\n\n      Intervention: the two parallel groups will receive the conventional therapy plus:\n\n        1. dexamethasone: 0'30 mg per kg every 12 hours during 3 days.\n\n        2. placebo (physiological saline)at the same dosing regimen.\n\n      Centralized lecture of the late DMSA after 6 months of the pyelonephritis episode will be\n      performed. Renal scarring presence and grade will be reported."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Those children between 2 months and 14 years with a provable acute pyelonephritis  that\n        fulfill the hospitalization criteria defined in the Spanish Clinical practice guide.\n        Briefly:\n\n          -  age under 3 months.\n\n          -  general affectation, toxic appearance.\n\n          -  vomiting or oral intolerance.\n\n          -  dehydration, bad peripheric perfusion.\n\n          -  or other intermedia situations that include:\n\n               1. high fever (>38.5 Celsius) in 3-6 month old children.\n\n               2. unusual germ risk factors.\n\n               3. family history of vesicoureteral reflux.\n\n               4. recurrent febrile urinary infections. With absence of a previous renal scarring\n                  objectivated after a DMSA.\n\n               5. high elevation of acute phase reactants.\n\n        Exclusion Criteria:\n\n          -  those eligible patients that do not fulfill the hospitalization criteria.\n\n          -  patients with a procalcitonin under 0.05 ng per ml.\n\n          -  patients with previous uropathy or renal scarring\n\n          -  patients allergic to dexamethasone.\n\n          -  endocrinologic disease.\n\n          -  history of cancer.\n\n          -  serious illness.\n\n          -  immunosuppressor treatment.\n\n          -  previous treatment with corticoids (continuous oral or parenteral treatment) during\n             the last 2 months.\n\n          -  the patient included in the study that do not present pyelonephritis after the acute\n             phase DMSA evaluation will be excluded.\n\n          -  the patient included in the study that suffered a second pyelonephritis episode\n             during the following 6 months (before the second DMSA evaluation) will be excluded\n             for the primary output analyses."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Years", 
            "minimum_age": "2 Months", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Those children between 2 months and 14 years with a provable acute pyelonephritis that\n        fulfill the hospitalization criteria defined in the Spanish Clinical practice guide."
            }
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034851", 
            "org_study_id": "IISPV_Pediatria_Dexcar", 
            "secondary_id": "2011-005805-66"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute pyelonephritis", 
            "Renal scarring", 
            "Dexamethasone", 
            "Children", 
            "Corticoids", 
            "Complementary treatment", 
            "Prevention strategy"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "juand.gonzalez2@carm.es", 
                    "last_name": "Gonzalez JD Juan David, MD PhD", 
                    "phone": "+34629684560"
                }, 
                "facility": {
                    "address": {
                        "city": "Cartagena", 
                        "country": "Spain", 
                        "state": "Murica", 
                        "zip": "E30202"
                    }, 
                    "name": "Hospital General Universitario Santa Luc\u00eda de Cartagena"
                }, 
                "investigator": {
                    "last_name": "Gonzalez JD Juan David, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reus", 
                        "country": "Spain", 
                        "state": "Tarragona", 
                        "zip": "E43204"
                    }, 
                    "name": "Iispv- Hospital Sant Joan de Reus"
                }, 
                "status": "Enrolling by invitation"
            }, 
            {
                "contact": {
                    "email": "msamper@piushospital.cat", 
                    "last_name": "Samper MA Manuel Andres, MD PhD", 
                    "phone": "977392065"
                }, 
                "facility": {
                    "address": {
                        "city": "Valls", 
                        "country": "Spain", 
                        "state": "Tarragona", 
                        "zip": "E43800"
                    }, 
                    "name": "Pius Hospital de Valls"
                }, 
                "investigator": {
                    "last_name": "Samper MA Manuel Andres, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "amadrid@vhebron.net", 
                    "last_name": "Madrid AD Alvaro Domingo, MD PhD", 
                    "phone": "+34934893082"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "E08035"
                    }, 
                    "name": "Hospital Maternoinfantil Vall D'Hebron"
                }, 
                "investigator": {
                    "last_name": "Madrid AD Alvaro Domingo, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gfraga@santpau.cat", 
                    "last_name": "Fraga MG Maria Gloria, MD PhD", 
                    "phone": "+34935537075"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "E08041"
                    }, 
                    "name": "Hospital de La Santa Creu I Sant Pau de Barcelona"
                }, 
                "investigator": {
                    "last_name": "Fraga MG Maria Gloria, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zairaibars@gmail.com", 
                    "last_name": "Ibars Z Zaira, MD PhD", 
                    "phone": "+34655462300"
                }, 
                "facility": {
                    "address": {
                        "city": "Lleida", 
                        "country": "Spain", 
                        "zip": "E25198"
                    }, 
                    "name": "Hospital Arnau de Vilanova de Lleida"
                }, 
                "investigator": {
                    "last_name": "Ibars Z Zaira, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pediatria@iispv.cat", 
                    "last_name": "Closa R Ricardo, MD PhD", 
                    "phone": "+34977295821", 
                    "phone_ext": "1463"
                }, 
                "contact_backup": {
                    "email": "pediatria@iispv.cat", 
                    "last_name": "Closa R Ricardo, MD PhD", 
                    "phone": "+34977759365"
                }, 
                "facility": {
                    "address": {
                        "city": "Tarragona", 
                        "country": "Spain", 
                        "zip": "E43007"
                    }, 
                    "name": "Iispv-Hospital Joan Xxii de Tarragona"
                }, 
                "investigator": [
                    {
                        "last_name": "Closa R Ricardo, MD PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Parada E Esther, MD PhD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "2", 
        "official_title": "Phase 3- Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection Episode as Renal Damage Prevention Strategy. DEXCAR", 
        "overall_contact": {
            "email": "pediatria@iispv.cat", 
            "last_name": "Escribano J Joaquin, PhD MD", 
            "phone": "+34977759364"
        }, 
        "overall_contact_backup": {
            "email": "natalia.ferre@urv.cat", 
            "last_name": "Ferre N Natalia, PhD", 
            "phone": "+34977759364"
        }, 
        "overall_official": [
            {
                "affiliation": "IISPV- URV-Hospital Universitari Sant Joan de Reus- Research unit in pediatrics, nutrition and human development", 
                "last_name": "Escribano J Joaquin, PhD MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "IISPV-URV- Hospital Universitari Joan XXIII de Tarragona-Research unit in pediatrics, nutrition and human development", 
                "last_name": "Closa R Ricardo, MD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "IISPV-URV-Research unit in pediatrics, nutrition and human development", 
                "last_name": "Ferr\u00e9 N Natalia, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL ARNAU DE VILANOVA DE LLEIDA", 
                "last_name": "Ibars Z Zaira, MD PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "HOSPITAL DE LA SANTA CREU I SANT PAU, DE BARCELONA", 
                "last_name": "Maria Gloria MG Fraga, MD PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "HOSPITAL MATERNOINFANTIL VALL D'HBRON, BARCELONA", 
                "last_name": "Madrid A Alvaro, MD PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Pius Hospital de Valls", 
                "last_name": "Samper M Manuel, MD PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "HOSPITAL GENERAL UNIVERSITARIO SANTA LUC\u00cdA DE CARTAGENA", 
                "last_name": "Gonzalez JD Juan David, MD PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "HOSPITAL JOAN XXII DE TARRAGONA", 
                "last_name": "Parada E Esther, MD PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad", 
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "renal scarring", 
            "safety_issue": "No", 
            "time_frame": "6 month after the acute pyelonephritis episode"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034851"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Institut Investigacio Sanitaria Pere Virgili", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Hospital Universitari Sant Joan de Reus", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hospital Universitari Joan XXIII de Tarragona.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Pius Hospital de Valls", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hospital Arnau de Vilanova", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Maternal-Infantil Vall d\u00b4Hebron Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Santa Luc\u00eda University General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Rovira i Virgili", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Institut Investigacio Sanitaria Pere Virgili", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "6 Months", 
        "verification_date": "April 2014"
    }
}